Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 28pembrolizumab 24Cisplatin 24Fluorouracil 11Leucovorin 10Oxaliplatin 8Nivolumab 7Capecitabine 6Irinotecan 5Drug Therapy 5pemigatinib 4futibatinib 4Paclitaxel 4Carboplatin 4ivosidenib 3fludarabine 3durvalumab 3derazantinib 3Folfox protocol 3Cyclophosphamide 3Bevacizumab 3zanidatamab 2spartalizumab 2olutasidenib 2lenvatinib 2infigratinib 2budigalimab 2Trastuzumab 2Ipilimumab 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cholangiocarcinoma × crenigacestat × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡